血浆钙保护蛋白作为巨细胞动脉炎炎症标志物的价值

Michael Stormly Hansen , Lene Terslev , Uffe Møller Døhn , Viktoria Fana , Mads Radmer Jensen , Anne Katrine Wiencke , Steffen Heegaard , Oliver Niels Klefter , Yousif Subhi , Jane Maestri Brittain , Niklas Rye Jørgensen , Steffen Hamann
{"title":"血浆钙保护蛋白作为巨细胞动脉炎炎症标志物的价值","authors":"Michael Stormly Hansen ,&nbsp;Lene Terslev ,&nbsp;Uffe Møller Døhn ,&nbsp;Viktoria Fana ,&nbsp;Mads Radmer Jensen ,&nbsp;Anne Katrine Wiencke ,&nbsp;Steffen Heegaard ,&nbsp;Oliver Niels Klefter ,&nbsp;Yousif Subhi ,&nbsp;Jane Maestri Brittain ,&nbsp;Niklas Rye Jørgensen ,&nbsp;Steffen Hamann","doi":"10.1016/j.ajoint.2025.100165","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Blood tests used in workup for giant cell arteritis (GCA) have shortcomings such as lack of disease specificity. We evaluated if plasma calprotectin at first clinical presentation could predict the final clinical diagnosis of GCA as evaluated at follow-up after six months.</div></div><div><h3>Design</h3><div>Prospective cohort study.</div></div><div><h3>Methods</h3><div>Blood was drawn at presentation in consecutive patients suspected of GCA. Plasma calprotectin was measured using the Gentian GCAL® Calprotectin Reagent Kit. The final diagnosis of GCA was given at six-month follow-up.</div></div><div><h3>Results</h3><div>Of 110 patients reviewed, 103 were eligible for data analysis, and 76 had plasma calprotectin analysis available. Of these 76, 44 (58 %) had a final diagnosis of GCA, 31 (41 %) had no GCA, and one case (1 %) was inconclusive. Plasma median calprotectin concentration was significantly higher in those with GCA than in those without (<em>p</em> &lt; 0.001). Comparing the upper reference limit of the Gentian GCAL® (≥0.970 mg/L) with the final clinical diagnosis, plasma calprotectin performed with sensitivity 67 % (95 %CI: 50–81 %) and specificity 75 % (95 %CI: 55–89 %). The area under the receiver operating characteristics curve (AUC) was 0.71 (95 %CI: 0.58–0.84). Accuracy was 70 % (95 %CI 58–81 %). Using an optimal ROC cut-off limit of 0.635 mg/L, test statistics reached sensitivity 87 % (95 %CI: 73–96 %), specificity 61 % (95 %CI: 41–79 %), AUC 0.74 (95 %CI: 0.61–0.87), and accuracy 76 % (95 %CI: 64–86 %).</div></div><div><h3>Conclusions</h3><div>Plasma calprotectin was elevated in cases where GCA was subsequently confirmed. The value of plasma calprotectin as an inflammatory marker in cases with suspected GCA warrants further studies.</div></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"2 4","pages":"Article 100165"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The value of plasma calprotectin as an inflammatory marker in giant cell arteritis\",\"authors\":\"Michael Stormly Hansen ,&nbsp;Lene Terslev ,&nbsp;Uffe Møller Døhn ,&nbsp;Viktoria Fana ,&nbsp;Mads Radmer Jensen ,&nbsp;Anne Katrine Wiencke ,&nbsp;Steffen Heegaard ,&nbsp;Oliver Niels Klefter ,&nbsp;Yousif Subhi ,&nbsp;Jane Maestri Brittain ,&nbsp;Niklas Rye Jørgensen ,&nbsp;Steffen Hamann\",\"doi\":\"10.1016/j.ajoint.2025.100165\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Blood tests used in workup for giant cell arteritis (GCA) have shortcomings such as lack of disease specificity. We evaluated if plasma calprotectin at first clinical presentation could predict the final clinical diagnosis of GCA as evaluated at follow-up after six months.</div></div><div><h3>Design</h3><div>Prospective cohort study.</div></div><div><h3>Methods</h3><div>Blood was drawn at presentation in consecutive patients suspected of GCA. Plasma calprotectin was measured using the Gentian GCAL® Calprotectin Reagent Kit. The final diagnosis of GCA was given at six-month follow-up.</div></div><div><h3>Results</h3><div>Of 110 patients reviewed, 103 were eligible for data analysis, and 76 had plasma calprotectin analysis available. Of these 76, 44 (58 %) had a final diagnosis of GCA, 31 (41 %) had no GCA, and one case (1 %) was inconclusive. Plasma median calprotectin concentration was significantly higher in those with GCA than in those without (<em>p</em> &lt; 0.001). Comparing the upper reference limit of the Gentian GCAL® (≥0.970 mg/L) with the final clinical diagnosis, plasma calprotectin performed with sensitivity 67 % (95 %CI: 50–81 %) and specificity 75 % (95 %CI: 55–89 %). The area under the receiver operating characteristics curve (AUC) was 0.71 (95 %CI: 0.58–0.84). Accuracy was 70 % (95 %CI 58–81 %). Using an optimal ROC cut-off limit of 0.635 mg/L, test statistics reached sensitivity 87 % (95 %CI: 73–96 %), specificity 61 % (95 %CI: 41–79 %), AUC 0.74 (95 %CI: 0.61–0.87), and accuracy 76 % (95 %CI: 64–86 %).</div></div><div><h3>Conclusions</h3><div>Plasma calprotectin was elevated in cases where GCA was subsequently confirmed. The value of plasma calprotectin as an inflammatory marker in cases with suspected GCA warrants further studies.</div></div>\",\"PeriodicalId\":100071,\"journal\":{\"name\":\"AJO International\",\"volume\":\"2 4\",\"pages\":\"Article 100165\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AJO International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2950253525000693\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJO International","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950253525000693","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的用于巨细胞动脉炎(GCA)检查的血液检查存在缺乏疾病特异性等缺点。我们评估了首次临床表现时的血浆钙保护蛋白是否可以预测6个月后随访评估的GCA的最终临床诊断。前瞻性队列研究。方法连续对疑似GCA患者就诊时抽血。血浆钙保护蛋白检测采用龙胆草GCAL®钙保护蛋白试剂盒。GCA的最终诊断在6个月的随访中给出。结果在110例患者中,103例符合数据分析,76例可进行血浆钙保护蛋白分析。在这76例中,44例(58%)最终诊断为GCA, 31例(41%)没有GCA, 1例(1%)不确定。GCA患者血浆钙保护蛋白中位数浓度显著高于无GCA患者(p < 0.001)。将龙胆草GCAL®的参考值上限(≥0.970 mg/L)与临床最终诊断结果进行比较,血浆钙保护蛋白的敏感性为67% (95% CI: 50 ~ 81%),特异性为75% (95% CI: 55 ~ 89%)。受试者工作特征曲线下面积(AUC)为0.71 (95% CI: 0.58 ~ 0.84)。准确率为70% (95% CI 58 - 81%)。采用最佳ROC截止限为0.635 mg/L,试验统计量达到敏感性87% (95% CI: 73 - 96%),特异性61% (95% CI: 41 - 79%), AUC 0.74 (95% CI: 0.61-0.87),准确性76% (95% CI: 64 - 86%)。结论GCA患者血浆钙保护蛋白升高。血浆钙保护蛋白在疑似GCA病例中作为炎症标志物的价值值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The value of plasma calprotectin as an inflammatory marker in giant cell arteritis

Purpose

Blood tests used in workup for giant cell arteritis (GCA) have shortcomings such as lack of disease specificity. We evaluated if plasma calprotectin at first clinical presentation could predict the final clinical diagnosis of GCA as evaluated at follow-up after six months.

Design

Prospective cohort study.

Methods

Blood was drawn at presentation in consecutive patients suspected of GCA. Plasma calprotectin was measured using the Gentian GCAL® Calprotectin Reagent Kit. The final diagnosis of GCA was given at six-month follow-up.

Results

Of 110 patients reviewed, 103 were eligible for data analysis, and 76 had plasma calprotectin analysis available. Of these 76, 44 (58 %) had a final diagnosis of GCA, 31 (41 %) had no GCA, and one case (1 %) was inconclusive. Plasma median calprotectin concentration was significantly higher in those with GCA than in those without (p < 0.001). Comparing the upper reference limit of the Gentian GCAL® (≥0.970 mg/L) with the final clinical diagnosis, plasma calprotectin performed with sensitivity 67 % (95 %CI: 50–81 %) and specificity 75 % (95 %CI: 55–89 %). The area under the receiver operating characteristics curve (AUC) was 0.71 (95 %CI: 0.58–0.84). Accuracy was 70 % (95 %CI 58–81 %). Using an optimal ROC cut-off limit of 0.635 mg/L, test statistics reached sensitivity 87 % (95 %CI: 73–96 %), specificity 61 % (95 %CI: 41–79 %), AUC 0.74 (95 %CI: 0.61–0.87), and accuracy 76 % (95 %CI: 64–86 %).

Conclusions

Plasma calprotectin was elevated in cases where GCA was subsequently confirmed. The value of plasma calprotectin as an inflammatory marker in cases with suspected GCA warrants further studies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信